99% Female Steroids Hormone Flibanserin for Gaining Women Sexy-Enhancement

Product

99% Female Steroids Hormone Flibanserin for Gaining Women Sexy-Enhance...

Posting date : Jun 19, 2017

Click enlarge Image

Membership

Free Member Scince May 06, 2017

FOB Price

USD1/Gram

Min. Order Quantity

10gram

Supply Abillity

5000kg/month

Port

Guangzhou

Payment Terms

wWestern Union,Money Gram,Bitcoin or Bank Transfer

Package

Discreet

Keyword :

Steroids Hormone

Category

Contact

Laura

0 likes

Product Detail

Company Info

Quick Detail

Place of Origin

China [CN]

Brand Name

kafen

Model Number

167933-07-5

HS-CODE

Package & Delivery Lead Time

Package

Discreet

Detailed Description

99% Female Steroids Hormone Flibanserin for Gaining Women Sexy-Enhancement

Basic Info: Product Name: FlibanserinChemical Name: Centrophenoxine HCLCAS Number: 167933-07-5EINECS Number: 222-975-3Molecular Formula: C20H21F3N4OMolecular Weight: 294.17Melting Point: 139-143℃Assay: 99.5%Appearance: White powder Product Description: Flibanserin is a novel, non-hormonal drug that has been studied in clinical trials for the treatment of HSDD in premenopausal and postmenopausal women. The application submitted to the FDA is for premenopausal women. Flibanserin is believed to work on key neurotransmitters, or chemicals, in the brain that affect sexual desire. More specifically, it is thought that flibanserin corrects an imbalance of levels of these neurotransmitters by increasing dopamine and norepinephrine (both responsible for sexual excitement) and decreasing serotonin (responsible for sexual inhibition). In clinical studies, flibanserin was evaluated for its ability to increase the frequency of satisfying sexual events, increase the intensity of sexual desire and decrease the associated distress women feel from its loss. Application: Flibanserin is being hailed as "Viagra for women." The experimental drug - designed for post-menopausal women with low sex drives - has now won approval from an advisory panel for the Food and Drug Administration (FDA).

Flibanserin is an antidepressant that failed to help depression in clinical trials, but was noted to have improved sexual health outcomes. It’s not uncommon for a drug to be developed for one purpose, then approved for another. Sildenafil (Viagra) was originally developed to lower blood pressure, but failed those trials. The benefit of both of these drugs was discovered by accident. However, flibanserin has now been studied for its effects on sexual health for nearly a decade.

Flibanserin doesn't have any interactions with hormonal medications, Thorp says. It does seem to interact with the original libido helper, though: some panelists recommended a warning against drinking alcohol while taking it, Reuters reported. (Interested in natural alternatives to hormone replacement therapy? The Natural Menopause Solution has everything you need to tame symptoms and trigger rapid, healthy weight loss in menopausal women.)

HSDD is the most commonly reported form of female sexual dysfunction. HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty, and which is not better accounted for by a medical, substance-related, psychiatric (e.g., depression) or other sexual condition. The cause of HSDD is believed to involve a multitude of social, psychological and biological factors and may be attributed toa complex interplay of these factors. Function: A new drug designed to boost sexual desire in women is controversial for some and eagerly awaited by others, but it's hit a potentially serious snag. The drug didn't boost women's desire any more than a placebo in two clinical trials. The Food and Drug Administration posted the clinical trial results on its website today in advance of a committee meeting on Friday, when a panel of experts will vote whether or not to recommend approval of the drug called flibanserin. (The FDA usually follows the recommendations of its expert panels.) Although there was a slight increase in the number of sexually satisfying events flibanserin users had each month, the FDA staff who reviewed the results said the so-called response rate isn't "particularly compelling."